Biopharmaceutical innovator Firebrick Pharma (ASX:FRE) has secured $1.5 million in firm commitments through a strategic placement.
The capital raise, supported by a mix of new and existing sophisticated investors, involves the issuance of approximately 31.9 million fully paid ordinary shares priced at $0.047 each.
The pricing reflects a 16.5% discount to the 15-day volume-weighted average price, signaling strong institutional appetite for the company's growth trajectory.
The infusion of liquidity is earmarked for a multi-pronged expansion strategy over the next 12 months.
Key priorities include aggressive business development, licensing activities, and the clinical advancement of two new pipeline products.
As an added incentive, investors will receive one free attaching option for every two shares issued, exercisable at $0.095 through July 2028.
The financial boost arrives on the heels of a transformative regulatory breakthrough in Indonesia.
Firebrick recently earned importation and distribution approval for its flagship Nasodine nasal spray, categorised as an 'antiseptic' household health supply.
With a population of 285 million, Indonesia represents the largest market in Southeast Asia and a "massive value inflection point," according to Executive Chair Dr Peter Molloy.
To navigate this complex market, Firebrick has partnered with PT Pyridam Farma Tbk to manage local regulatory and Ministry of Health interactions.
At the time of reporting, Firebrick Pharma's share price was $0.063.